Jan 09,2023

Dario Publishes New Research in Peer Reviewed Journal Demonstrating Improved Outcomes by Race Race and Ethnicity

DarioHealth Corp., a leader in the global digital therapeutics (DTx) market, has published new research in the peer-reviewed journal Applied Sciences showing that users with Type 2 diabetes from different racial and ethnic groups had improved outcomes using their digital therapeutics platform. The new research examined retrospective data from 1,000 users with Type 2 diabetes who engaged with Dario’s platform across a 12-month period. The study found no statistical difference in engagement levels and significant improvements in average blood glucose across all groups over a 12-month period.

CLINICAL STUDY

#dtx

#coaching

View Analyst & Ambassador Comments
Go to original news
Jan 09,2023

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook

DexCom, Inc. today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be at least $815 million, an increase of 17% over the fourth quarter of 2021 on a reported basis and 20% on an organic basis. U.S. revenue is expected to be approximately $606 million, representing growth of 17% over the fourth quarter of 2021. International revenue is expected to be approximately $209 million, an increase of 15% over the fourth quarter of 2021 on a reported basis and 26% on an organic1 basis. For fiscal 2022, total preliminary, unaudited revenue is expected to be approximately $2.91 billion, an increase of 19% over 2021 on both a reported and organic basis.

View Analyst & Ambassador Comments
Go to original news
Jan 09,2023

EOFlow submits wearable, disposable insulin patch pump for FDA 510(k) clearance

EOFlow announced recently that it submitted a 510(k) application to the FDA for its EOPatch wearable, disposable insulin pump. San Jose, California-based EOFlow submitted its application on Dec. 27, 2022. It aims to enter the U.S. diabetes market, expanding its reach outside Korea. The wearable, disposable device features a glucose monitoring sensor, insulin pump and automated insulin delivery algorithm.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jan 09,2023

Dexcom appoints former J&J exec as CCO, sets 2023 guidance

Dexcom announced today that it appointed Teri Lawver to its newly created role of chief commercial officer (CCO). Lawver’s position oversees the global commercial organization at the continuous glucose monitoring (CGM) technology developer. She holds responsibility for global sales, marketing and customer experience. Before joining San Diego–based Dexcom, Lawver spent two decades in a variety of leadership roles at Johnson & Johnson. Her positions spanned the medical device, consumer medtech and pharmaceutical sectors. Most recently, she served as worldwide VP, immunology at J&J’s Janssen Pharmaceutical Companies.

View Analyst & Ambassador Comments
Go to original news
Jan 09,2023

Beta Bionics appoints new CMO as it prepares for artificial pancreas launch

Beta Bionics announced that it appointed Dr. Steven Russell as its chief medical officer (CMO) as it readies itself for a major product launch. Russell, an endocrinologist and diabetologist, brings 20 years of experience in diabetes management. He serves as an associate professor of medicine at Harvard Medical School. He also works as an attending physician at Massachusetts General Hospital Diabetes Associates.

View Analyst & Ambassador Comments
Go to original news
Jan 10,2023

Carbon Health announces $100M in funding days after revealing layoffs

Carbon Health announced that the hybrid care provider had received $100 million in Series D investment from CVS Health Ventures days after revealing a second round of layoffs in the past year. The Series D funds will help Carbon Health scale its Connective Care model, which uses software to connect patients and healthcare providers, and allows for digital monitoring and management of care.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Jan 10,2023

Hygieia Expands to Arizona, as Endocrinology Associates, PA, Joins d-Nav® Insulin Management Clinical Partnership Program

Hygieia, a provider of digital therapeutics for insulin management, has added Endocrinology Associates, PA, in Scottsdale and Chandler, AZ, as a clinical partner. With the d-Nav clinical partnership, endocrinologists can ensure their patients receive necessary dose adjustments whenever needed, without an office visit. This significantly frees-up the physician’s time and provides improved glucose management for patients.

COLLABORATION PARTNERSHIP

#institution

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 11,2023

DreaMed Diabetes Deploys Diabetes Data Management and Clinical Decision Support Device Into Patients’ Electronic Medical Records at Yale New Haven Health

DreaMed Diabetes, a developer of AI-based diabetes care solutions, partnered with Yale New Haven Health System Center for Health Care Innovation and successfully deployed DreaMed’s endo.digital clinical decision support system as a fully integrated component of Northeast Medical Group’s EMR workflow. The endo.digital system pushes critical patient information, such as glucose statistics, into the EMR flowsheet and progress notes. The patient’s approved care plan is delivered directly to the patient via the endo.digital patient app

COLLABORATION PARTNERSHIP

#institution

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 11,2023

This AI-based smartphone app helps diabetes patients manage blood sugar

Oregon Health & Science University (OHSU) combined AI and diabetes experts to develop a smartphone app to help manage blood sugar levels. They plan to organize a randomized clinical trial to evaluate an enhanced app used in concert with diabetes education specialists. The Leona M. and Harry B. Helmsley Charitable Trust awarded the university more than $4.3 million to support the work.

PRODUCT

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Jan 11,2023

Tandem Diabetes Care expects double-digit revenue growth in 2023

Tandem Diabetes Care announced preliminary fourth-quarter results and offered expectations for the coming year. San Diego-based Tandem expects sales to total $221 million, coming in $11 million higher than the same quarter last year. Wall Street analysts expected $221.6 million in revenues. However, the automated insulin delivery technology developer noted that its adjusted sales rise to $224 million for the quarter.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES